PCRX vs REG · P/E 174, rev $369.8M vs P/E 34, rev $1.45B
Pacira BioSciences, Inc. (PCRX) versus Regency Centers Corporation (REG) — a side-by-side from cached financials, not a winner call.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Regency Centers Corporation (REG) is a reit - retail company listed on US.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Latest reported REG revenue for 2024-12-31 was $1.45B. Net income was $409.8M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. REG currently screens at market cap $12.93B and trailing P/E 33.5.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2. REG currently screens at market cap $12.93B and trailing P/E 33.5.
Not investment advice. Open the PCRX and REG stock pages for the full models.
Not investment advice.